Screener
Wave Life Sciences WVE AATD Program — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development expenses: | ||||
| INHBE program | $6,870 | $3,515 | $11,706 | $6,054 |
| AATD program | 2,989 | 1,846 | 4,739 | 3,292 |
| DMD program | 3,953 | 2,681 | 8,091 | 5,719 |
| HD program | 157 | 789 | 220 | 1,956 |
| Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM | 37,324 | 34,638 | 73,977 | 67,070 |
| Total research and development expenses | 51,293 | 43,469 | 98,733 | 84,091 |
| General and administrative expenses | 24,781 | 17,989 | 46,884 | 36,346 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's AATD program — research and development expense?
- Wave Life Sciences (WVE) reported AATD program — research and development expense of $2.99M in Q2 2026.
- How has Wave Life Sciences's AATD program — research and development expense changed year-over-year?
- Wave Life Sciences's AATD program — research and development expense increased by 61.9% year-over-year, from $1.85M to $2.99M.
- What is the long-term trend for Wave Life Sciences's AATD program — research and development expense?
- Over 3 years (2022 to 2025), Wave Life Sciences's AATD program — research and development expense has grown at a 14.9% compound annual growth rate (CAGR), from $3.76M to $5.71M.
- What does AATD program — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research and development activities of the Alpha-1 Antitrypsin Deficiency (AATD) therapeutic program. It captures expenditures related to clinical trials, preclinical studies, and scientific innovation specifically focused on advancing this pipeline asset. Monitoring this expense provides insight into the company's capital allocation strategy and the pace of development for this specific genetic disorder treatment.
Ask your AI about Wave Life Sciences's aatd program — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude